Clinical Trial Update: A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas [Phase 1]

View source ↗

Summary

This document reports the status of a Phase 1 clinical trial evaluating GLB-002 in patients with relapsed or refractory Non-Hodgkin Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• GLB-002

Snippet

Sponsor: Hangzhou GluBio Pharmaceutical Co., Ltd. | Conditions: Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING